Sequentia Biotech

Executive Summary

Sequentia Biotech is a Spanish bioinformatics company founded in 2016 that specializes in transforming complex omics data into actionable insights. The firm offers expert data analysis, custom software development, and consulting services to a diverse clientele spanning academia, pharmaceuticals, clinical diagnostics, agriculture, and the food industry. Its proprietary analysis platforms, GAIA® and MICK®, alongside sequencing services and training, position it as a versatile partner in the genomics space. Despite operating as a private company with no disclosed funding rounds or valuation, Sequentia has built a niche in the European bioinformatics market by focusing on tailored solutions and multi-sector applicability. The company's growth trajectory is supported by increasing demand for bioinformatics services driven by the expansion of genomic research and precision medicine. However, its limited public profile and lack of disclosed financials constrain visibility. Overall, Sequentia Biotech is well-positioned to capitalize on the growing need for specialized omics data interpretation, though its impact remains regionally focused and dependent on further commercialization and partnerships.

Upcoming Catalysts (preview)

• Q4 2026Launch of new bioinformatics platform or major update to GAIA/MICK30% success
• H2 2026Strategic partnership with a pharmaceutical or agricultural company25% success
• TBDDisclosure of Series A funding round or significant grant15% success